Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- LDP Subcommittee Holds Hearing on Unification of Dispensing Fees
July 25, 2011
- “Biosimilars Era”Coming to Japan: Mr Sawai of JGA
July 25, 2011
- JPA to Collect ADR Avoidance Case Reports from Pharmacies
July 25, 2011
- Merck Serono to Enter 2nd High Growth Stage after Stable Growth in 2011-2012: President Smith
July 25, 2011
- No Major Obstacle to Japan's Participation in PIC/S: Chairman Graberg
July 25, 2011
- Teva Obtains All Shares from Taiyo Pharm. for ¥74 Bil.
July 25, 2011
- APEX to Build Up Nationwide Network
July 25, 2011
- Drug Production in March Down as Much as 65% in 3 Quake-hit Prefectures: Korosho
July 25, 2011
- Rivaroxaban Approved for Prevention of DVT in the US
July 25, 2011
- HPB Issues Notification Aimed at Increasing Efficiency of Clinical Trials
July 25, 2011
- J-CKDI Predicts Dialysis Patients to Decrease after Peak in 2017
July 25, 2011
- Antiepileptic Agent Rufinamide Approved in Canada: Eisai
July 18, 2011
- Over 70% of Women Aware of HPV Vaccine: Survey
July 18, 2011
- FDA Committee Recommends Withdrawal of Breast Cancer Indication from Avastin
July 18, 2011
- Bristol-Myers to Create Friendlier Work Environment for Women
July 18, 2011
- Council on Unapproved Drugs to Revise Assessment Criteria
July 18, 2011
- STATISTICS
July 18, 2011
- Sales of Ethical Drugs Up 7.5% in May: Crecon & Research Consulting
July 18, 2011
- Bayer Aiming for Top-10 Spot in Global Ethical Drug Market by 2015
July 18, 2011
- JACDS, JPA to Cooperate Regarding nternet Drug Sales, Unification of Basic Dispensing Fees
July 18, 2011
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…